Want to see TSE:CSCI full AI Analyst Report?
CSCI Stock Chart & Stats
C$2.80
--
Market closed
C$2.80
--
Day’s Range― - ―
52-Week RangeC$3.30 - C$18.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)2.48K
Market Cap
C$8.49M
Enterprise Value-C$1.80
Total Cash (Recent Filing)C$5.01M
Total Debt (Recent Filing)C$2.02M
Price to Earnings (P/E)―
Beta2.58
Next Earnings
Aug 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-15.42
Shares Outstanding1,061,386
10 Day Avg. Volume3,973
30 Day Avg. Volume2,485
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.57
Price to Sales (P/S)0.29
P/FCF Ratio-0.23
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Manageable Balance SheetSustained low debt-to-equity (~0.13) gives the company structural financial flexibility to endure ongoing losses, fund operations or R&D from equity or cash, and reduces near-term default risk. That balance-sheet headroom supports a multi-month runway while management pursues commercialization or pipeline milestones.
Positive TTM Revenue MomentumConsistent trailing-twelve-month revenue growth (~6.3%) signals improving product uptake or commercial traction rather than a one-off. Over a 2–6 month horizon this sustained top-line momentum can help absorb fixed costs, provide evidence of market demand, and form the base for future margin improvement if cost structure is managed.
Historical Ability To Reach ProfitabilityRecorded positive net income in 2021–2022 demonstrates the business model can reach profitability under the right conditions. This provides a durable precedent that operations and cost controls can be aligned to be profitable, reducing structural execution risk relative to companies with no profitable history.
Bears Say
Persistent Negative Cash FlowLarge and ongoing negative operating and free cash flow (~-$8.7M to -$8.8M TTM) is a structural weakness that will deplete liquidity absent meaningful margin improvement or new financing. Over months this forces reliance on external capital, increasing dilution risk and constraining investments in commercialization or R&D.
Deep Operating Losses And Negative MarginsSeverely negative EBIT/EBITDA and net margins indicate the current cost base and revenue scale are not delivering sustainable profits. Structural margin deficits limit internal cash generation, require substantial scaling or cost restructuring to reverse, and present a multi-month challenge to reach break-even without material business changes.
Volatile Equity / Financing And Dilution RiskDocumented volatility in equity levels implies past reliance on financing actions and a real risk of future equity raises. Given continued cash burn, this structural financing need can dilute shareholders, complicate long-term ownership incentives, and create uncertainty around capital allocation and governance in the coming months.
COSCIENS Biopharma News
CSCI FAQ
What was COSCIENS Biopharma’s price range in the past 12 months?
COSCIENS Biopharma lowest stock price was C$3.30 and its highest was C$18.00 in the past 12 months.
What is COSCIENS Biopharma’s market cap?
COSCIENS Biopharma’s market cap is C$8.49M.
When is COSCIENS Biopharma’s upcoming earnings report date?
COSCIENS Biopharma’s upcoming earnings report date is Aug 13, 2026 which is in 25 days.
How were COSCIENS Biopharma’s earnings last quarter?
COSCIENS Biopharma released its earnings results on May 12, 2026. The company reported -C$0.702 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is COSCIENS Biopharma overvalued?
According to Wall Street analysts COSCIENS Biopharma’s price is currently Overvalued.
Does COSCIENS Biopharma pay dividends?
COSCIENS Biopharma does not currently pay dividends.
What is COSCIENS Biopharma’s EPS estimate?
COSCIENS Biopharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does COSCIENS Biopharma have?
COSCIENS Biopharma has 1,061,386 shares outstanding.
What happened to COSCIENS Biopharma’s price movement after its last earnings report?
COSCIENS Biopharma reported an EPS of -C$0.702 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.896%.
Which hedge fund is a major shareholder of COSCIENS Biopharma?
Currently, no hedge funds are holding shares in TSE:CSCI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
COSCIENS Biopharma
COSCIENS Biopharma Inc., a life science company, develops and commercializes products for the cosmeceutical, nutraceutical and pharmaceutical markets in the United States, Germany, the United Kingdom, and internationally. It operates through Active Ingredient and Pharmaceutical segments. The company offers active ingredients comprising oat beta glucan, a functional ingredient that supports overall health and wellness; oat powder and peptides; oat oil which is extracted from whole oat kernels by a gentle process that retains all the important biologically active components; and avenanthramides, a natural-based ingredients used to inflammation-based diseases for the cosmeceutical and pharmaceutical industries. It also provides Macrilen/Ghryvelin (macimorelin), an orally active peptidomimetic small molecule that stimulates the secretion of growth hormone from the pituitary gland. The company sells its products through its distribution network. It has license agreements with Pharmanovia, Davimed GmbH, and NK MEDITECH Ltd, as well as Agriculture Canada, Canadian Government, and University of Alberta. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is based in Toronto, Canada.
Technical Analysis
BetterLife Pharma
―
PharmaTher Holdings Ltd
―
Glow LifeTech
―
Marvel Biosciences Corp
―
PharmAla Biotech Holdings, Inc.
―